The Position of Multikinase Inhibitors in the Era of Immune-Checkpoint Inhibitors for Hepatocellular Carcinoma

Gut Liver. 2024 Jan 15;18(1):3-4. doi: 10.5009/gnl230505.

Author

Beom Kyung Kim^{1

2

3}

Affiliations

¹ Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
² Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea.
³ Yonsei Liver Center, Severance Hospital, Seoul, Korea.

No abstract available

Publication types

Editorial

MeSH terms

Antibodies, Monoclonal / therapeutic use
Carcinoma, Hepatocellular* / drug therapy
Carcinoma, Hepatocellular* / pathology
Humans
Immune Checkpoint Inhibitors / therapeutic use
Immunotherapy
Liver Neoplasms* / drug therapy
Liver Neoplasms* / pathology
Phenylurea Compounds / pharmacology
Phenylurea Compounds / therapeutic use

Substances

Immune Checkpoint Inhibitors
Antibodies, Monoclonal
Phenylurea Compounds